Focus: Sellas Life Sciences is a public-stage oncology-focused immunotherapy biotech company developing cancer vaccines and cellular therapies, headquartered in New York. The company operates as a pre-revenue clinical-stage enterprise with a focused pipeline in hematologic malignancies and solid tumors.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Sellas Life Sciences Group to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Sellas Life Sciences Group
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sellas Life Sciences Group's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside - Stocktwits
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside Stocktwits
Top AgomAb Therapeutics (AGMB) Competitors 2026 - MarketBeat
Top AgomAb Therapeutics (AGMB) Competitors 2026 MarketBeat
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Analysts’ Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX) The Globe and Mail
Sellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish Signal (NASDAQ:SLS) - Seeking Alpha
Sellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish Signal (NASDAQ:SLS) Seeking Alpha
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus - TechStock²
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus TechStock²
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and Protara Therapeutics (TARA) The Globe and Mail
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission.
The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo